A multidisciplinary approach involving both pulmonologists and rheumatologists may lead to earlier ILD diagnosis among patients with SARDs.

Clinical improvements were achieved and maintained for up to 3 years among bDMARD-naïve patients with PsA who received bimekizumab.

Patients with systemic vasculitides vs healthy controls were associated with elevated risks for both osteoporosis and fragility fractures.

Treatment with open-label tofacitinib improved disease activity among patients with sJIA but did not significantly prolong the time to flare compared with placebo.